SCHEMBL6491502

SCHEMBL6491502

COC(=O)c1ccc(NC(C)=O)c([N+](=O)[O-])c1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 6/20 0.42
NPSR1 Q6W5P4 2/20 0.41
GALR2 O43603 1/20 0.41
MITF O75030 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 1/20 0.41
XBP1 P17861 1/20 0.41
CCR6 P51684 1/20 0.41
MAPT P10636 2/20 0.41
COMT P21964 1/20 0.41
MEN1 O00255 3/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8953331 0.86 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2
SCHEMBL5988015 0.84 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2
SCHEMBL7414257 0.84 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2
SCHEMBL9076418 0.81 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KMT2ANPSR1LMNA
SCHEMBL20165830 0.81 KMT2A (0.46) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL13705663 0.80 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2
SCHEMBL13088439 0.77 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2
SCHEMBL31521308 0.77 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1KMT2ALMNAHPGD
SCHEMBL6504817 0.76 FSCN1 (0.39) SMN1; SMN2ALDH1A1KMT2APOLBCOMT
SCHEMBL1919472 0.75 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1KMT2ANPSR1GALR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974817-B2 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) PFIZER INC. (US) 2005-12-13 US disclosed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A SMN1; SMN2 325/4885ALDH1A1 476/4885KMT2A 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.